With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-167-Tenet Healthcare

The health care services company operates 65 hospitals and approximately 450 other facilities in addition to providing health care support services to clients. In April, Tenet announced it completed the sale of its urgent care platform to FastMed for $80 million.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

F500-2020-174-Tenet-Healthcare

The Dallas-based health care company and its subsidiaries operate acute care and specialty hospitals, as well as ambulatory surgery centers and other health care facilities around the U.S.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Fortune Global 500

Sector

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Tenet Healthcare operates a network of hospitals, acute care centers, emergency departments, imaging centers, and ambulatory surgery centers through its subsidiaries and joint ventures, comprising one of the largest for-profit hospital chains in the U.S. Its Conifer Health Solutions subsidiary provides revenue cycle management to hospitals and health systems nationwide.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Tenet Healthcare (THC): Company Profile, Stock Price, News, Rankings

legacy

Tenet Healthcare

tenet healthcare

Good morning, and welcome to Tenet Healthcare's 1st quarter 2026 earnings conference call. After the speaker remarks, there'll be a question and answer session for industry analysts. At that time, if you'd like to ask a question, please press star one to enter the question queue. Tenet respectfully asks that the analysts limit themselves to one question each. I'll now turn the call over to your host, Mr. Will McDowell, Vice President of Investor Relations. Mr. McDowell, you may begin.

Good morning, everyone, and thank you for joining today's call. I am Will McDowell, Vice President of Investor Relations. We're pleased to have you join us for a discussion of Tenet's first quarter 2026 results, as well as a discussion of our financial outlook. Tenet senior management participating in today's call will be Dr. Saum Sutaria, Chairman and Chief Executive Officer, and Sun Park, Executive Vice President and Chief Financial Officer. Our webcast this morning includes a slide presentation which has been posted to the investor relations section of our website, tenethealth.com. Listeners to this call are advised that certain statements made during our discussion today are forward-looking and represent management's expectations based on currently available information. Actual results and plans could differ materially. Tenet is under no obligation to update any forward-looking statements based on subsequent information.

Investors should take note of the cautionary statement slide included in today's presentation, as well as the risk factors discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. With that, I'll turn the call over to Saum.

All right. Thank you, Will, and good morning, everyone. In the first quarter, we reported net operating revenues of $5.4 billion and consolidated adjusted EBITDA of $1.16 billion, which represents an adjusted EBITDA margin of 21.6%. We are pleased with the start to the year, performing above our previously provided expectations. As anticipated towards the end of last year, the operating environment is dynamic. There are payer mix shifts, seasonal effects, and insurance enrollment uncertainty in the exchanges and Medicaid that impact demand. Despite these challenges, we delivered a clean quarter characterized by disciplined operations, benefits from execution on our previously described expense opportunities, stable volumes despite headwinds, and as a result, significant free cash flow generation.

USPI generated $484 million in adjusted EBITDA, which represents six percent growth over the first quarter of 2025 and a robust 22% of our full year 2026 adjusted EBITDA guidance. We are pleased with USPI's start to the year as we set an aggressive EBITDA target as a percent of the full year for the first quarter that we were able to exceed. We have seen a pattern over the last few years with a modest shift towards an increased distribution of cases and therefore earnings into the first quarter. Given our focus on acuity, same facility revenues grew five point three percent at USPI, highlighted by double-digit same-store volume growth in total joint replacements in the ASCs over prior year. Our operations in the first quarter were somewhat impacted by two major winter storms and uncertainty from vendor cyberattacks.

However, our operating teams managed through them and were able to reschedule many of the procedures, lessening the overall impact in the quarter. We have a robust pipeline of assets interested in joining USPI this year. As such, we've had a particularly strong start to the year, investing $125 million in the first quarter to acquire seven ASCs. Additionally, we have commenced patient care at three de novo centers. This represents half of our targeted full-year spend already completed in the first quarter. Turning to our hospital segment, first quarter 2026 adjusted EBITDA was $678 million, which was nicely above our expectations and represented 27.5% of our full year 2026 adjusted EBITDA guidance.

We reported 16.7% EBITDA margins in the quarter, which were driven by disciplined expense management and growth initiatives, which offset the expected impacts of unfavorable payer mix and re-reductions in exchange enrollment. The results in the quarter reflect no significant changes in supplemental Medicaid program revenues compared to our original expectations. We have seen declines in exchange coverage, with same-store exchange admissions down about 10% compared to first quarter 2025, but not yet at the level we assumed as the average for the full year. We continue to assess the overall environment for effectuation rates and the impact on future exchange volumes. We believe we have the tools to manage this impact under a variety of scenarios. We continue to make investments in technology to enable growth and streamline operations.

We are executing on the expense initiatives that we discussed on our Q4 2025 earnings call and are recognizing the benefits. These initiatives include engagement tools which are improving recruitment and retention efforts, process automation to address length of stay, and capacity controls which improve our clinical throughput. Among these things, we are executing on AI-related capabilities in our hospitals, physician practices, and the global business center to drive further efficiencies. Most of which have been useful for supporting extending the productivity metrics of our team. Importantly, we have learned that while all of these tools will not work in a pilot state, setting up a governance that either green lights for rapid scaling up or red lights for shutdown help us remain focused.

We have included third-party EMR integrated solutions which will increase our clinician productivity, decrease administrative burden, and improve patient access through programs such as Ambient Scribe, automated discharge summaries, and autonomous professional fee coding in various pilot programs. Additionally, we have increased back-office AI automation, which is improving productivity and consolidating third-party spend to reduce costs. For example, we have almost doubled or more the productivity of our Conifer analytics team. As we look forward, we are actively identifying and piloting agentic workflows to transform further business processes. So far, our work has enabled us to more than offset the expected and an unexpected headwinds that arose in the quarter. Regarding full year 2026 guidance, as in prior years, at this time, we are not addressing the underlying outperformance in our business units during the first quarter.

We're pleased with our year-to-date performance, we're reaffirming our full year guidance, and we'll address our expectations for the full year in the future. As a reminder, after normalizing for the non-recurring items that were reported in 2025 and the first quarter of 2026, and excluding the headwind from the expiration of the Premium Tax Credit, our 2026 adjusted EBITDA is expected to grow at 10% at the midpoint of our range. Finally, we continue to see significant opportunity to utilize share repurchase at our current valuations. We repurchased 1.35 million shares for $318 million in the first quarter of 2026, and expect to continue to deploy capital for share repurchase over the balance of the year.

In conclusion, we adapt to the environment, focus on strong clinical quality, recommit to helping our doctors have an easier environment to operate in, and focus on delivering reliable earnings in this transitionary period. Our balance sheet is strong, our diversified asset mix with a focus on ambulatory care gives us a significant strategic advantage in the market as we look ahead. With that, I will turn it over to Sun for more details. Sun.

Thank you, Saum, Good morning, everyone. We had a nice start to the year in the first quarter of 2026, generating total net operating revenues of $5.4 billion and consolidated adjusted EBITDA of $1.162 billion. First quarter adjusted EBITDA margin was 21.6%, driven by disciplined operating expense management, including good progress on the expense initiatives that we outlined last quarter. I would now like to highlight some key items for both of our segments, beginning with USPI. In the first quarter, USPI's adjusted EBITDA was $484 million, with adjusted EBITDA margin at 36.7%. USPI delivered a five point three percent increase in same-facility system-wide revenues, with net revenue per case up five point six percent and same facility case volumes down zero point three percent.

As Saum noted, volumes were impacted by the winter storms early in the quarter, and while we were able to reschedule many of the procedures, there was an overall impact. Turning to our hospital segment. First quarter 2026 adjusted EBITDA was $678 million, resulting in an adjusted EBITDA margin of 16.7%. This represents 27.5% of our expected full year 2026 adjusted EBITDA. Same-hospital inpatient adjusted admissions rose zero point six percent in the quarter and were impacted by a decline in respiratory admissions of 41% compared to first quarter of 2025. This driver represented a 90 basis point reduction in admissions growth in the quarter.

Revenue per adjusted admissions declined one point five percent year-over-year in first quarter of 2026 due to the impact of reduced Exchange volumes within our overall payer mix and the year-over-year impact of the $40 million favorable out-of-period supplemental Medicaid revenues that we reported in the first quarter of 2025. Exchange revenues represented about six percent of consolidated revenues in first quarter of 2026, a nine percent decline from first quarter of 2025. Our consolidated Salary, Wages, and Benefits was 40.5% of net revenues in the quarter, consistent with our performance from the prior year, despite the net revenue headwinds, demonstrating our ability to flex our operating model. Overall, operating expenses per adjusted admissions were also favorable to our expectations, which contributed to our outperformance in the quarter.

In the first quarter of 2026, we recognized a one-time approximate $40 million favorable revenue adjustment as a result of the completed Conifer transaction. This amount was included in our original guidance. I would also note that this adjustment is not included in our revenue per adjusted admission calculations. We recorded supplemental Medicaid revenues of $304 million in the first quarter of 2026, consistent with what we assumed in our guidance. Importantly, we did not benefit from out-of-period supplemental Medicaid revenues related to prior years in this quarter. We're pleased with our ability to manage through the various dynamics throughout our first quarter and feel we have the ability to deliver on our commitments over the balance of the year. Next, we will discuss our cash flow, balance sheet, and capital structure.

We generated $978 million of adjusted free cash flow in the first quarter. As of March 31, 2026, we had $2.97 billion of cash on hand, with no borrowings outstanding under our line of credit facility. Additionally, we have no significant debt maturities until late 2027. Finally, during the first quarter, we repurchased 1.35 million shares of our stock for $318 million. Our leverage ratio as of March 31st, 2026, was two point two four times EBITDA or two point eight three times EBITDA less NCI, driven by our strong operational performance and financial discipline. We remain committed to maintaining a deleveraged balance sheet and believe that we have significant financial flexibility to support our capital deployment priorities and drive shareholder value.

Let me now turn to our outlook for 2026. As Saum noted, we are not making any adjustments to our full year 2026 outlook at this time. While we have strong fundamental outperformance in the first quarter and have continued confidence in our ability to achieve our full-year targets, it is early in the year, and we will plan to revisit our full-year guidance as needed in subsequent quarters. As such, we are reaffirming the full year 2026 guidance that we initially provided in February. Our outlook continues to exclude any contributions from potential increases in supplemental Medicaid programs that have not yet been approved and finalized by CMS. For second quarter of 2026, we expect consolidated adjusted EBITDA to be 24%-25% of our full-year consolidated adjusted EBITDA at the midpoint.

We expect that USPI's EBITDA in the second quarter will also be 24% to 25% of our full-year 2026 USPI EBITDA at the midpoint. Turning to our cash flows for 2026, we continue to expect adjusted free cash flow after NCI in the range of $1.6 billion to $1.83 billion. This range includes the payment of about $150 million in tax payments for the Conifer transaction this year. Excluding these tax payments, this would represent $1.865 billion of adjusted free cash flow after NCI at the midpoint of our 2026 outlook. We remain focused on strong free cash flow conversion from our EBITDA performance, including the continued outstanding cash collection performance of Conifer, while continuing to invest in high-priority areas of our businesses.

Turning to our capital deployment priorities, we are well positioned to create value for shareholders through the effective deployment of free cash flow. First, we will continue to prioritize capital investments to grow USPI through M&A. As Saum noted, we have had a strong start to the year and have a number of future opportunities to support our $250 million annual target for USPI M&A. Second, we expect to continue investing in key hospital growth opportunities to fuel organic growth, including our focus on higher acuity service offerings. Third, we'll continue to be active in share repurchases. We continue to see significant opportunity at our currently compressed valuation multiples. Finally, we will continue to evaluate opportunities to retire and/or refinance debt.

We are pleased with our strong start to the year and remain confident in our ability to deliver on our outlook for 2026. We continue to execute our strategy across our transformed portfolio of businesses, resulting in a more predictable, more capital-efficient company that is well positioned to drive value through effective capital deployment. With that, we're ready to begin the Q&A. Operator?

Thank you. At this time, we'll be conducting a question-and-answer session. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. As a reminder, Tenet respectfully asks that analysts limit themselves to one question each. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Our first question comes from Ryan Langston with TD Cowen. Your line is now live.

Great. Thank you. Payer denials this year appear to be broadly accelerating across the industry. Are you seeing this activity increase in your business? Maybe is it more MA versus commercial? Is the rise in uninsured or uncompensated care you're seeing primarily related to the exchange subsidy expiration, or is there anything else you'd call out there? Thank you.

Thanks for the question. I mean, denials, I would say payer disputes, many of which can result in denials and a back and forth, are high. They have been high. As I've said before, they're too high for what is appropriate, especially when comparing back to kind of pre-pandemic periods, just as a marker. I don't think that in our business we have seen a net impact of disputes and denials changing in this quarter relative to before, so meaning last year. Look, they're high. They have been too high, but, you know, we don't see a meaningful trend this quarter that's different.

We can only guess, obviously, with the slight increase in uncompensated care that some of it has to do with the expiration of the exchange subsidies.

Our next question comes from A.J. Rice with UBS. Your line is now live.

Thanks. Hi, everybody. You know, if I look at the last number of quarters, there's been consistency of outperformance in the hospital segment overall. I wonder if you could talk maybe broadly, because we haven't talked about markets in a general sense. Are there some markets where you've implemented strategies that you'd call out that have been particularly successful? As you look across the portfolio, maybe discuss some markets that still have an opportunity for significant improvement as you deploy new strategies to improve their performance.

Thanks, A.J., I appreciate your calling out the strength of the hospital business over the last few years. You know, we have been focused on a broad strategy of obviously increasing acuity, focusing on our ability to succeed with our transfer centers, adding new surgical programs and increasing our emergency-related services, especially trauma programs and other things. You know, in a combined sense, it's a global strategy. I mean implemented locally, we have opportunities and are implementing in every market that we have. As you're aware, based upon the portfolio shifts that we made, we remained in markets in which we thought the execution of our overall strategy would be successful.

You know, look, there are things like, for example, enrollment in the exchanges that differ state to state and what the impact will be. There are some differences there in terms of what's happening, in terms of throughput and other things that it may impact, even the uninsured piece. If you step back and now sort of with my commentary today, which is that, you know, we're in this transitionary period where there's some coverage changes that are occurring. You know, we'll see how all that settles out. When you look at the opportunity to find efficiencies, you look at the support services for the hospitals and you look at some of the automation opportunities that I described, once again, those are available in each market.

Of course, some markets are bigger than other markets, so at a $ level, you might get more impact in one market than another. They're scaled appropriately and are available in each of the markets. If you look at our earnings in the first quarter, you know, this year, they were driven by consistency across our markets in terms of the efficiency opportunities. Look, the other thing I would point out is just good old-fashioned discipline around flexing our cost structure. We kinda knew early in the year by the time we had given guidance that one of the winter storms had already come through. You know, we were able to maintain our SWB as a percentage of our top line by flexing, even though the revenues were gonna be a little bit more challenged.

You know, some of this is just continuing to maintain the old-fashioned, you know, quote-unquote, "old-fashioned discipline," the discipline of anticipating and flexing inter-quarter, which of course is also an opportunity available in all markets. I hope that helps.

Our next question comes from Jason Cassorla with Guggenheim Partners. Your line is now live.

Great. Thanks. Good morning. I wanted to go back to your prepared remarks around your efforts around length of stay and throughput improvements. You're clearly seeing the benefits there, given length of stay has been down about three percent in each of the past six quarters, by our math. That improvement is coming despite your high acuity service line focus, which would naturally carry a higher length of stay. I guess, could you just double a little bit more on the length of stay opportunity for you and what that run rate looks like, as you move through the rest of the year and beyond? Thanks.

Yeah. No, I appreciate the question. You're right that the two are actually coupled in an interesting way, which is in order to maintain available capacity to always service the high acuity needs that arise in the community, whether from direct direct arrival at our hospitals or for outlying hospitals that might need help or support, which we always try to say yes to, you have to make sure that your throughput and capacity management is good enough to have the availability of beds to be able to say yes for those things. We see the two being very intricately linked in terms of a requirement to succeed in the high acuity strategy.

Look, you're right that as the acuity goes up, there's a length of stay headwind that does come with it because the cases are more complex and longer. We're pleased with the fact that we are managing that overall length of stay to something better than even break even in terms of our reported length of stay because that's creating capacity in our hospitals. You know, I would remind everybody that part of the strategy, of course, is, you know, capital avoidance on additional capacity that's really not necessary when you can improve productivity that way.

Again, for us, all these things are intricately linked and, you know, look, we're pleased that some of these new tools that we're trying out are helping to add to our more traditional length of stay management that we've talked about over the last four or five years.

Our next question comes from Brian Tanquilut with Jefferies. Your line is now live.

Hey, good morning, Saum. This is a tough quarter, congrats on beating that UNDA line. Maybe just on the Medicaid side, you know, a lot of your peers have spoken about Medicaid trends, whether that's immigrants not filling out paperwork and just curious, what are you seeing in the Medicaid book? As we've seen uncompensated care step up here, which was all seen across the space, right? How much of that is Medicaid versus maybe exchange members versus other dynamics? Thanks.

No, I appreciate it. Obviously it's somewhat speculation, but I guess we sort of speculate based on our markets, so I'll be a little bit careful of how sure I am in my answers. I would say that, you know, look, Medicaid is down a little bit, and we see a little bit more of that in places like California. That does suggest that some of what's happened is either dis-enrollment or lack of renewal of enrollment with populations that may not have been qualified to begin with based upon at least federal regulations. That's one fact point that we see.

You know, the second question that has been out there, especially because we are in a lot of important border communities where we do a lot of work for the broader communities that are there. Look, we do see a little bit of hesitation at times with those populations. We partner a lot with the important FQHCs in those markets and, you know, there's just kind of this tone of hesitation. The impact at the end of the day has been on the hospitals, you know, minimal because obviously we're there taking care of people who are sick and have needs.

On the outpatient side, you know, for people who are doing more primary care and other things in the community, we, you know, we're hearing about a little bit more impact and, certainly hesitation from coming in to consume care.

Our next question comes from Scott Fidel with Goldman Sachs. Your line is now live.

Hi. Thanks. Good morning. I think my question probably ties in to the last two, wanted to ask it from the acuity and case mix perspective, overall for both the hospital and USPI, how those rates look year-over-year, and maybe you could layer in on the tailwind side, the proactive service line expansions and investments that you've made on higher acuity. On the headwind side, obviously some of these dynamics or dynamics relating to the dynamic environment that we saw in some of the ad markets in the first quarter. Thanks.

Sure. Well, let's start with USPI. I mean, there's no question there about the increase in acuity. I mean, I called out. I mean, we obviously are, on the outpatient side, you know, probably the largest single provider of outpatient joint replacements when you collectively look at, you know, almost 570 assets at USPI, many of which do orthopedics, and we're still posting double-digit growth in total joint replacement surgeries within the ASCs and, you know, off of a pretty high base. It just suggests the demand is out there, right? If you create the right operating environment for these surgeons and give them an efficient, safe way to do the work, the demand is out there. We continue pushing in our, you know, high acuity strategy.

I mean, you can see it in the revenues. And, you know, when you add to that, as you ask for other service lines, the types of things we're doing in urology, the types of things we're doing in robotics, we're probably up to over 150, you know, robotic surgery programs in the ASCs that are general surgery-based. Those types of things are growing quickly. I mean, the only services that are declining are the high volume, low acuity areas, you know, which is, as we've said, we're less focused on in this diversification path. Again, in summary, on the USPI side, the acuity is growing, the case mix is improving in the direction we want to. We have a good number of service line starts and physician additions.

The assets that we're acquiring are also supportive more of the service line strategies that we're interested in. Our de novos that we open will also have the opportunity to do this type of higher acuity work. I would say that that looks very good. On the hospital side, you know, the journey that we've been on is I mean, we made this decision in the very early part of the pandemic. It's been five years that we've been really pushing this high acuity strategy, and you see it in the CMI, the margins, the net revenue per case, you know, all of that. This quarter obviously has some differences that Sun can go into in terms of the comp to the first quarter last, you know, last time with a bunch of one-time items.

You know, look, the CMI for the first time was down a little bit. You know, this is temporary, right? We had some weather-related issues. We certainly had a decline in the intensity and volume of the respiratory business. As I said, you know, we made up for that significantly by flexing and also by focusing more on some of our other type of work in the hospitals. You know, I think the quarter ended up fine. Like, I don't think anything changes going forward just because there was one quarter with significant respiratory impact.

Our next question comes from Craig Hettenbach with Morgan Stanley. Your line is now live.

Yes, thank you. On the back of the $125 million invested in USPI in Q1, really strong start to the year. Saum, can you just talk about the M&A engine, what's working, and also just context of why Tenet might be a preferred acquirer of choice out there in the marketplace?

Yeah, well, I mean, I think, what's working, fundamentally what's working is that USPI has just got a multi-year track record of acquiring assets, adding value to them, both clinically, you know, our quality performance is consistent. Our ability to bring these facilities in-network and do well is consistent. Our broad-based and ongoing supply chain and purchase services agenda helps to reduce costs and create efficiencies. Our business development team, you know, is terrific at helping these centers, oftentimes go from single specialty to multi-specialty or help them design their OR operations if they're already multi-specialty, to be able to do those more efficiently. As I've always talked about, right?

The ability to do kind of, quote, "dirty and clean surgery in the same center with the right protocols and the right scheduling." I mean, all of these things are things that we work on consistently, we're just ahead in the market when it comes to executing on these things. I think physicians know that. I think many of the MSOs that we partner with know that. The health systems that we partner with, not only know that, because of the expertise of some of these health systems, they contribute actively to our quality improvement agenda and other things. I mean, Baylor, Memorial Hermann, I mean, these guys are experts in many of these areas, and they contribute actively to the partnership in USPI to make those improvements.

Look, I think all of those things has created a nice virtuous cycle of reputation enhancement as we do these things and we deliver on what we say we're going to do. We're still very selective. Our diligence processes are robust. We still say no to more centers than we say yes to. And that's fine because we still think that the opportunity for high-quality ASCs supports USPI's growth algorithm.

Our next question is from Justin Lake with Wolfe Research. Your line is now live.

Thanks. Good morning. Just a couple of numbers questions for me. First, your guidance assumes $250 million of exchange impact for the year. Apologize if I missed it, but did you have a number for the quarter, maybe relative to what we would have thought maybe is a $60 million-$65 million run rate? On DPP, in your slides, you talked about $22 million, the DPP down $22 million for the year. I'm curious, does this include the $40 million decline because of out-of-period so that you were actually up $18 million ex that? Thanks.

Yeah, good question. Sun, you wanna take those maybe in reverse order?

Yeah. Hey, Justin, it's Sun. Yeah, you're right on the DPP question. That includes the $40 million. If you normalize for that, for 25 out-of-period, then it'd be a slight increase. You're correct. On the HIX, you know, we mentioned that exchange revenues in Q1 was about six percent of our consolidated revenues. As a comparator in Q1 of 2025, it was about six and a half of our consolidated revenues. You know, if you kinda do the algebra, it's about a nine to 10% decrease in revenues versus Q1. You know, I would say it's roughly at, you know, half of kind of the overall one year, kind of 20% reduction in volumes that we kinda talked about in February.

You know, we do expect with all the dynamics around kinda the first quarter and the grace period with some of the enrollees or re-enrollees that, you know, I think our guidance range of kinda 20% reduction and $250 million overall impact is still pretty consistent.

Our next question comes from Kevin Fischbeck with Bank of America. Your line is now live.

Great. Thanks. Yeah, I guess, two questions. One maybe following up on that one. So the Q1 impact is lower. Is it lower but in line with what you thought Q1 would be because you always assumed it would ramp, or was that a potential area of the outperformance? Then you talked a little bit earlier about flu. I know one of your competitors had a pretty high margin in decremental margin on lost volume in Q1. It sounds like you did a better job flexing costs. Any way to kinda size what you think the EBITDA impact was to both USPI and the hospitals from the flu and the weather disruption? Thanks.

Yeah. Hey, it's Saum Sutaria. I can take the latter part of it. I mean, I don't know about flu specifically, but just, I mean, we look at respiratory, ER traffic, admissions, and other things. Similar to what we've heard, you know, for example, respiratory admissions were down like 40% in the quarter, and it had an earlier effect. I mean, if I look at the quarter January to February to March, things improved steadily month-over-month, week-over-week, almost. That by the time we were in March and, you know, the early to middle part of March, we had a keen sense that the revenue and admission and volume intensity was increasing. Because we had kind of anticipated the impact early in the quarter, we had already done some of our cost flexing.

Of course, as we talked about or previewed on our fourth quarter call, we had developed a more systematic type of cost agenda in the second half of 2025 that we executed that added to our savings. It created a situation in which the anticipation of the need to flex, plus our other cost improvements, plus the month-over-month improvement during the quarter, allowed us to outperform in the hospital segment what our expectations were despite some of these headwinds. You know, I mean, in terms of what our expectations were, we had sort of made a simple linear assumption. I would say that the outperformance in the quarter in the segment is a combination of the two things.

One being, the cost management and efficiencies, and two being, that the first quarter exchange impact was probably a little bit less than, at least a simple linear, you know, assumption for the full year.

Our next question comes from Ann Hynes with Mizuho. Your line is now live.

Hi, good morning. Maybe we can shift to the Washington outlook. Is there anything that you're paying attention to on the regulatory and legislative outlook, especially on the regulatory with the upcoming outpatient rule? Is there anything that is on your radar screen that we should be aware of? Thanks.

Sure. I mean, obviously, we're keenly awaiting the outpatient rule, especially given the type of policy commentary that's been coming out of CMS, HHS broadly, and CMS, supporting, you know, care in lower cost settings. One of the ways to help that, of course, is to provide more robust outpatient rate support relative to what was, you know, sort of as expected, nothing incredibly positive on the IPPs side. We're looking forward to seeing that. I would tell you know, other than the commentary they're making, I don't have any proprietary insights to share. We of course, have been following all of the discussion and commentary about the various parts of the sector.

You know, look, it's from our perspective, we're just trying to stay on the right side of the value equation, having efficient health systems, being accessible at all times, efficient in what we're doing, and obviously providing surgical care at scale at, you know, half the cost sometimes of what it is to do the same work in a hospital. With USPI, I mean, so look, I think all of those things, we feel like we're well-positioned, as we, as we look ahead. I mean, you know, if you really look at USPI, and I know this question was asked maybe as a sub-question earlier by Kevin.

USPI had an even cleaner quarter, despite all the, you know, noise because, you know, the weather impact was there, but you don't really see that much of an impact from the exchanges or Medicaid in that business, as we've pointed out before.

Our next question comes from Pito Chickering with Deutsche Bank. Your line is now live.

Hey, good morning, guys, and thanks for taking my questions. Looking back to hospitals, looking at your first quarter. You know, I understand that there's, you know, $20 million less of loan payments offset by recoveries of $40 million this quarter. When we normalize sort of the margins, you know, sort of get to, you know, I guess, you know, the 15% range is generally where your guidance is. If I think about margins for hospitals, generally, you know, they, you know, the year is better than just the first quarter because of the strong fourth quarter. I guess, can you just walk me through how we should think about the hospital margins with 1Q, excluding the $40 million as a bridge into the rest of the year? Thank you.

Well, I'll start, Sun, if you wanna add. I mean, look, I think that if you step back to our guidance for the year, which is in the hospital segment, a 10% normalized year-over-year growth, which, you know, there was obviously some discussion and dialogue about when we put it out there. We feel very confident that we're on track to that. Now, some of that's gonna be margin improvement. Some of that is because we had visibility from our work in the second half of 2025, which was going to be expense management, execution of expense management initiatives that we were designing this year that we would see benefit this year. Obviously, those are margin enhancing.

I don't know that the algorithm is exactly like it would be in a normal year. You know, the respiratory volume impact in Q1 is a headwind to margins because those tend to be capacity filling and margin accretive. We overcame that, as we sort of return to normal operations, plus have a year where we are executing on a broader efficiency strategy, I would say that, you know, we think that this year's performance will support margin growth in the hospital segment.

Sun, I don't know if you wanna add to that, but like We feel very confident about the balance of the year.

Yeah, I think that's right. The only thing I would add, Pito, is if you, if you kinda just look at our Q1 hospital margin of 16.7%, you're right. We should normalize for the one-time Conifer $40 million. The only other thing I would mention is, you know, like we said, the exchange impact likely sort of grows over the rest of the year from what we had in Q1. That probably, you know, damps down margin a little bit on a run rate basis. When it's all said and done, as Saum said, if you look kind of our full year guidance of sort of 15% implied margins, I think that's still right on our expectations.

I mean, you know, on the HIX impact, I get, you know, the guidance that, you know, that you gave for in the first quarter. The uninsured payer mix declined year-over-year in the first quarter. I thought that would have been increasing. I guess you know, how does that fit within that HIX guidance you guys have provided? Thank you.

I mean, look, I think we should watch and wait, right? I mean, effectuation rates and other things are important to track. The first quarter often is a relief valve for payment of premiums and other things. I would say we watch and wait. From our perspective, the way we think about this year is anticipate that the challenge could increase and plan accordingly in a disciplined way to manage to the earnings guidance that we have given. I mean, if obviously, if the impact is less or if the uninsured impact, you know, doesn't increase as much, those are all opportunities for outperformance for us. I mean, I would just reiterate, we're not spending a lot of time thinking about downside risks right now.

We're spending our time thinking about how the strategy in both segments, plus our expense opportunities, plus how this exchange, uninsured Medicaid market plays out, could create upside opportunities for us. That's where our mindset is right now after this first quarter.

Our next question comes from Whit Mayo with Leerink Partners. Your line is now live.

Hey, thanks. I just wanted to hear more about the reserving and revenue recognition for the exchange patients, what the underlying estimates are for attrition and maybe what the exit rate on the decline in volumes was within March. Thanks.

Hey, Whit. Yeah, hey, Whit, it's Sun. Listen, I think on a, on your first question, you know, we obviously pay through Conifer very close attention, you know, patient by patient, if we can, on, you know, their HIX coverage status, premium payment status, all those details that you would imagine. I think, you know, again, we'll review this as the year develops and we get more data, but I think we're very appropriately reserved on our overall patient population, right? Including HIX. That sort of speaks to kind of, you know, the numbers that we shared in Q1, where admissions were down, as we said, nine percent. If you do the algebra, I think revenues from HIX is down probably nine to10% as well.

It's sort of one to one, is where we're sitting. I think we're in a very reasonable situation there. Like we said, we'll, you know, continue to observe this as we go. From a month-over-month trend perspective, I mean, our overall volumes, not just HIX, but overall improved, you know, through the course of Q1, coming into March, which again, I think gives us, you know, some confidence into our rest of year guidance. On HIX, I don't know that there's any trends that we would point out.

You know, I think in January being sort of a grace period for a lot of the enrollees, I mean, I think that did help January numbers somewhat, but, you know, again, it's too early to kind of have any, have any trend discussions.

Our next question comes from Stephen Baxter with Wells Fargo.

Hi, thanks. I wanted to ask about the same-store revenue per adjusted admission decline of a point and a half in the first quarter. I guess we do have a lot of moving parts with, you know, some of the Medicaid changes you discussed and also the exchanges. On the other hand, you also have, you know, less flu, which I think would trend to push up some of those metrics. I'd hope to just get a better sense of, you know, some of the moving parts that impacted that metric, and then, you know, maybe a direct comment on what you're seeing on commercial mix and whether that's a headwind in the quarter that you might assume gets better through the balance of the year. Thank you.

Yeah, I mean, we should probably just start with the comp from the prior year and then the math, 'cause it's for us, it really wasn't that worrisome. Sun, I don't know if you wanna just walk through that perhaps.

Yeah, I think just on a pure algebra basis, I mean, you know, we said NRAA was down one point five percent in the hospital segment. A lot of that, you know, between the $40 million of out-of-period Medicaid we recognized in Q1 that we didn't have in Q1 of 2026. The reduction in HIX that, you know, as we talked about, presumably, moved volume into uncompensated or other payer classes. Those two combined, I think, was worth two to two and a half percent of NRAA headwind. Once you normalize for that, we're sort of at, you know, 50 basis points to one percent. I think there are some other moving parts that we talked about.

You know, Sun, I don't know if you wanna comment directly on flu, but yeah, I think flu impacted our admissions, but in the scheme of our total adjusted admissions base and our net revenue base, it's a relatively small component. Whether or not flu was there or not, I don't know that impacts NRAA that much.

The only other thing I would add is, it's a clarifying point, but also the one-time Conifer $40 million that we announced, even though it was part of the hospital segment, we excluded that in looking at the NRAA, 'cause that's appropriate. It wasn't related to the, you know, case volume, but just in case anybody's looking at the math that way. In summary, you know, look, I would say the biggest driver was this out-of-period thing, and we had a very high NRAA in 2025. Back to my overall commentary. The acuity strategy is working very well and we're not worried about it. Obviously, it did not have an impact. In fact, it was the opposite.

You know, we outperformed on the earnings despite the revenue, which is just right now a marker of the flexibility and operating discipline I think that's required in this environment as things settle out. I suspect in the, you know, coming months and when we talk again, we'll probably have a lot more insight into how, you know, I sense the desire for predictability, how the exchange market and uninsured and Medicaid will settle out for this year, which will give us a much better opportunity to kind of update our guidance for the year based upon the outperformance so far.

Our final question is from Andrew Mok with Barclays Bank. Your line is now live.

Hi. Good morning. You mentioned that ACA volumes were down 10% and you had expected, you know, unfavorable payer mix. When I look at the managed care mix disclosure, it actually looks relatively stable year-over-year. Can you help us understand what you saw on payer mix inside of that, including the moving parts on the government side? Thanks.

Tenet Healthcare (THC) Q1 2026 Earnings Call Transcript

Company Participants